Academic Radiology
Volume 17, Issue 2 , Pages 188-193 , February 2010

Dynamic Contrast Enhancement of Experimental Glioma: An Intra-individual Comparative Study to Assess the Optimal Time Delay

  • Tobias Engelhorn, MD

      Affiliations

    • Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    • Corresponding Author InformationAddress correspondence to: T.E.
    • ,
  • Marc A. Schwarz, PhD

      Affiliations

    • Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    • ,
  • Ilker Y. Eyupoglu, MD

      Affiliations

    • Department of Neurosurgery, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    • ,
  • Stephan P. Kloska, MD

      Affiliations

    • Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    • ,
  • Tobias Struffert, MD

      Affiliations

    • Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany
    • ,
  • Arnd Doerfler, MD

      Affiliations

    • Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany

Received 13 July 2009 ,Accepted 14 August 2009.

References 

  1. Trattnig S, Ba-Ssalamah A, Noebauer-Huhmann IM, et al. MR contrast agent at high-field MRI (3 Tesla). Top Magn Reson Imaging. 2003;14:365–375
  2. Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34:45–60
  3. Schneider G, Kirchin MA, Pirovano G, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging. 2001;14:525–539
  4. Ba-Ssalamah A, Nöbauer-Huhmann IM, Pinker K, et al. Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol. 2003;38:415–422
  5. Erickson BJ, Campeau NG, Schreiner SA, et al. Triple-dose contrast/magnetization transfer suppressed imaging of “non-enhancing” brain gliomas. J Neurooncol. 2002;60:25–29
  6. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol. 2002;37:269–280
  7. Engh JA, Flickinger JC, Niranjan A, et al. Optimizing intracranial metastasis detection for stereotactic radiosurgery. Stereotact Funct Neurosurg. 2007;85:162–168
  8. Reifenberger G, Bilzer T, Seitz RJ, et al. Expression of vimentin and glial fibrillary acidic protein in ethylnitrosourea-induced rat gliomas and glioma cell lines. Acta Neuropathol. 1989;78:270–282
  9. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998;36:91–102
  10. Wintersperger BJ, Runge VM, Biswas J, et al. Brain tumor enhancement in MR imaging at 3 Tesla. Comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558–563
  11. Kim B, Chenevert TL, Ross BD. Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Clin Cancer Res. 1995;1:643–650
  12. Berens ME, Giese A. “Those left behind.” Biology and oncology of invasive glioma cells. Neoplasia. 1999;1:208–219
  13. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia. 1995;15:328–338
  14. Pinkernelle J, Teichgraeber U, Neumann F, et al. Imaging of single human carcinoma cells in vitro using a clinical whole-body magnetic resonance scanner at 3.0 T. Magn Reson Med. 2005;53:1187–1192
  15. Barth RF. Rat brain tumor models in experimental neurooncology: the 9L, C6, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998;36:91–102
  16. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244–248
  17. Yrjänä SK, Vaara T, Karttunen A, et al. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol. 2008;43:267–275
  18. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715–724
  19. Vonarbourg A, Sapin A, Lemaire L, et al. Characterization and detection of experimental rat gliomas using magnetic resonance imaging. MAGMA. 2004;17:133–139

PII: S1076-6332(09)00504-2

doi: 10.1016/j.acra.2009.08.014

Academic Radiology
Volume 17, Issue 2 , Pages 188-193 , February 2010

Article Tools

* Image Usage & Resolution